anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, hormones. SUBSTANCE: invention relates to new methods of administration of parathyroid hormone and compositions of its biologically active fragment. The systemic delivery of parathyroid hormone in mammalian-host is performed by orally as a dispersion of N-terminal fragment of parathyroid hormone. This respiratory route of delivery of parathyroid hormone fragment provides the pulsing pattern of serum blood concentration of parathyroid hormone fragment. Compositions of parathyroid hormone fragment involve preparations of parathyroid hormone as dry powder, liquid solutions or suspensions able for spraying and aerosol propellents able for use in an inhaler as fixed doses. EFFECT: broadened arsenal of agents for administration of hormonal preparations in body. 21 cl, 2 dwg, 12 ex
New method of extraction of plant flavonoids by extracting with aq. acetone at room temp., evaporating the acetone under reduced pressure, saturatin the aq. concentrate with NaCl, filtering off the pptated. condensed tannins, extracting the flavonoids with an immiscible organic solvent in which the flavonoids are not denatured, dehydrating the flavonoid solution and precipitating them by adding an organic solvent in which they are insol. and which mixes in all proportions with the flavonoid solvent collecting the ppte and drying it; in which the dehydrated flavonoid soln. is obtained by saturating the aq. soln. of flavonoids with NaCl, filtering, and extracting the filtrate with butanol, evaporating to dryness the butanol extract, under reduced pressure, extracting the residue with ethanol/ethyl acetate to give a dehydrated solution, then precipitating the flavonoids by adding to the soln. an anhydrous ether, esp. diethyl ether.
The present invention concerns a method for the establishment of pluripotent human blastocyst-derived stem (BS) cell line, stem cells obtained by the method, differentiation of these cells into differentiated cells, the differentiated cells and the use of these differentiated cells in the preparation of medicaments. The undifferentiated pluripotent stem cells can be made to differentiate to a number of specialized cell types which can be utilized in the manufacture of medicaments for treating a number of conditions or pathologies involving degeneration of tissue e.g. of the pancreas leading to e.g. development of diabetes, or of the CNS (e.g. Alzheimer's, Parkinson's disease etc.) or degeneration of the CNS caused by e.g. stroke or physical trauma.
The present invention relates to a tumbler including a medicine case which notifies a user of the medication intake time and stores the medication history in a smartphone. The medicine case tumbler consists of: a medicine case (100) with a notification function; a tumbler lid (200) that connects the medicine case and the tumbler using screw threads; and a tumbler body (300) that holds water. The present invention sets off an alarm at the time of medication intake through a speaker and a vibrator of the medicine case, as well as smartphone notifications, and records the intake on the smartphone via a sensing unit that includes a lid switch on the lid of the medicine case. Moreover, when the medicine case is a certain distance away from the smartphone, a notification pops up on the smartphone. As such, the medicine case and the tumbler can be combined or disassembled as needed. Also, the present invention solves the issue of missing or forgetting medication intake times through the alarm of the medicine case that rings at the set time chosen by the user via the app while automatically recording the intake time on the smartphone, preventing confusion about medication intake and thus avoiding situations like overdosing. Furthermore, the present invention has the effect of preventing the user from forgetting or leaving the medicine case by the smartphone notification which pops up when the smartphone is a certain distance away from the medicine case.
The utility model belongs to the drug, in particular to an ointment. The novel ointment comprises a base and a drug layer and also comprises a protection layer and a connection layer. The protection layer is connected with the drug layer which integrates the base. The base is connected with the connection layer and has a gap with the drug layer. The gap can form random pattern. The ointment can be glued to the affected part when using, which can't move along with the movement of joints, thereby the novel ointment of the utility model can't slip easily and can be removed when the potency of drug is exerted.
Myeloid derived suppressor cells (MDSCs) are a heterogenous population of immature hematopoietic precursors with known immunoregulatory functions. The immunosuppressive role of MDSCs has been highlighted in several inflammatory ophthalmic disorders; however, their therapeutic application in suppressing the immune-mediated changes in dry eye disease (DED) has not been studied. We observed significant reduction in antigen presenting cell (APC) frequencies and their maturation in the presence of MDSCs. Moreover, co-culturing MDSCs with T helper 17 cells (Th17) resulted in reduced Th17 frequencies and their IL-17 expression. On the contrary, MDSCs maintained regulatory T cell frequencies and enhanced their function in-vitro. Furthermore, we delineated the role of interleukin-10 (IL-10) secreted by MDSCs in their immunoregulatory functions. We confirmed these results by flow cytometry analysis and observed that treatment with MDSCs in DED mice effectively suppressed the maturation of APCs, pathogenic Th17 response, and maintained Treg function and significantly ameliorated the disease. The results in this study highlight the potential therapeutic application of MDSCs in treating refractory DED.
Eligible patients after signing the informed consent and will undergo study evaluation and then typed for acetylator phenotype before being treated with hydralazine at 182 mg for rapid-, or 83 mg for slow-acetylators, and magnesium valproate at 30 mg/kg, starting from day -7 until chemotherapy ends. Chemotherapy will consists in a regimen of four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days, followed by surgery to assess the pathological response. Adjuvant radiation and additional treatment will be done in off-protocol basis according to standard institutional policies. Blood samples and core-needle biopsies will be taken from primary breast tumors at diagnosis and at day 8 of treatment with hydralazine and valproate. Global cytosine content (global DNA methylation) and histone deacetylase activity will be assessed in peripheral blood DNA. The transcriptional profile in the primary breast tumor before and after treatment will also be analyzed as well as the plasma levels of hydralazine and valproic acid.
PURPOSE: To provide a physiological activity promoter intended to promote human health through activating somatic cells, containing a high nucleic acid material and chitosan. CONSTITUTION: This physiological activity promoter contains, as the chief ingredients, a high nucleic acid material and chitosan, and, according as needed, at least one kind, in the form of powder, selected from anhydrous lactose, cornstarch, phosphoric acid compounds and sucrose. This promoter is made into a preparation in the form of tablets, or encapsulated, in power or granules, into e.g. water-soluble gelatin to be made into capsules. The high nucleic acid material is e.g. soft roes of salmon or swellfish, beer yeast, and the chitosan is obtained by alkali treatment of chitin constituting lobster or crab crust. The weight ratio of the high nucleic acid material to chitosan lies between (50:13) and (40:25).  Since this promoter contains the high nucleic acid material and chitosan which is to be excreted after adsorbing cholesterol, the absorption of cholesterol through intestinal canal is effectively restrained even after intake of cholesterol-rich high nucleic acid materials.
The present invention discloses a complete set of Chinese medicine preparations for converting hepatitis B viruses into negative, which is composed of a first prescription, a second prescription and a third prescription, wherein the first prescription is composed of the following 19 raw materials: 2.5 to 4% of honeycomb, 7 to 9.5% of astragalus root, 2 to 3% of wild chrysanthemum flower, 3 to 5% of giant knotweed, etc.; the second prescription is composed of the following 20 raw materials: 3 to 4.5% of atractylode, 3 to 4.5% of frankincense, 8 to 13% of human placenta, etc.; the third prescription is composed of the following 19 raw materials: 12 to 17% of artemisiae scopariae, 4 to 12% of red sage root, 0.9 to 3.5% of zedoary rhizome, etc. The first prescription and the second prescription are made into powder, and the third prescription is made into oral liquid. The three medicines can be matched to respectively play the roles of killing or inhibiting viruses, promoting liver cell growth, strengthening body immunity and regulating integral function. The Chinese medicine preparations has definite curative effect on the negative conversion of hepatitis B antigens and antibodies, and has obvious comprehensive curative effect on various acute hepatitis and chronic hepatitis.
PROBLEM TO BE SOLVED: To provide a decolorant component and hair dye composition capable of reducing irritating smells. SOLUTION: The decolorant composition to be used in combination with an oxidizing agent includes (a) at least one selected from ammonia and ammonium salts, (b) an alkanolamine, (c) an ester-type nonionic surfactant and (d) water. The hair dye composition includes (e) a dye in addition. The content of the component (a) is preferably 0.08-0.98 wt.% calculated as ammonia. The content of the component (b) is preferably 2.0-6.0 wt.%. Further, the content of the component (c) is preferably 1.5-10.0 wt.%. The decolorant composition and the hair dye composition are each constructed to an oil-in-water type emulsion by addition of a higher alcohol and an oil component and the formulation of the higher alcohol further includes the formation of liquid crystal structures in them, respectively.
FIELD: medicine, neurosurgery. SUBSTANCE: a traumatic intramedullar cyst is evacuated, its wall is damaged. One should introduce a transplant of fetal spinal cord enriched with lining cells of olfactory nerve bulbs. Suspension of viable nerve cells in combination with blood-producing cells should be, also, introduced into subarachnoid space of a spinal cord. The method could be applied in traumatology, transplantology and rehabilitation. EFFECT: higher efficiency of therapy. 3 dwg, 2 ex
This study is a single-center, observational, non-interventional, prospective study. 50 patients diagnosed with stage IIIB-C driver-negative NSCLC receiving induction chemoimmunotherapy will be planned to be enrolled in the study. Pre-treatment biopsy tissues of enrolled patients will be collected for next-generation sequencing (NGS) of institutionally-developed 1021-gene panel, and personalized detection panel will be customized based on NGS testing results. Patients will be received induction chemoimmunotherapy followed by surgery or non-surgical treatment in the MDT model and ctDNA-MRD testing will be performed at prespecified time points. For patients who received surgery following induction therapy, peripheral blood will be collected in baseline, 1 day before the third cycle of neoadjuvant therapy, 1 day before surgery, 3 days after surgery and landmark time and pulmonary venous blood will be collected intraoperatively. For patients who received non-surgical treatment following induction therapy, peripheral blood will be collected in baseline, 1 day before the third cycle of neoadjuvant therapy, 1 day before non-surgical therapy and landmark time. All included patients will be regularly followed up for at least 5 years.
FIELD: agriculture, veterinary science. SUBSTANCE: the suggested method includes introduction of oil-water emulsion at the dosage of 9.82-14.03 g for sick cow 3-6 h after calving pararectally into area of hypogastric nerve plexus. This emulsion contains medicinal substances at the following ratio of components, weight%: synestrol, 2%-oily solution 17.82-18.3, Novocain 17.82-18.3, sunflower oil 49.9-51.0, phenol 0.2-0.21, distilled water the rest. The present method is highly efficient in case of afterbirth retaining and treating endometritis in cows. EFFECT: higher efficiency. 1 tbl
Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
The prevalence of obesity has increased tremendously in the past two decades. An estimated 1 out of 5 persons in the United States are classified as obese. Under representation of obese patients in pharmacokinetic trials grossly limit generalizability of drug dosing recommendations in this emerging population. No published pharmacokinetic studies of voriconazole dosing in patients with obesity currently exist in the literature. Specifically,voriconazole pharmacokinetic data from subjects with a body mass index (BMI) ≥ 35 kg/m2(Class II and III obesity) are limited.

Voriconazole is available as both an intravenous and oral formulation. Anecdotal experience suggest that the use of oral voriconazole to be significantly more prevalent that that of intravenous therapy. The current oral recommended dosing regimen for voriconazole includes use of 200 mg every 12 hours for patients who are over 40 kg. The dosage can be increased to 300 mg by mouth every 12 hours in situations where a sufficient clinical response is not noted. A weight based dosing strategy is also utilized in patients with more serious infections (3-6 mg/kg IV Q 12 hours) such as invasive aspergillosis. Voriconazole demonstrates non-linear pharmacokinetics and so dosing based on total body weight may result in non-dose proportional exposure. For example, a 1.5 fold dose increment in voriconazole from 200 mg to 300 mg every 12 hours results in a 2.5 fold increase in exposure. The most appropriate body size descriptor is unknown (i.e. ideal body weight, fat free weight, lean body weight, etc.) for most antimicrobials, including voriconazole. As a consequence, the appropriateness of weight-based voriconazole dosage selection in obese patients is not known. Intuitively, weight based dosing (on total body weight) in this population could lead to higher than expected exposures (non-linear pharmacokinetics) and lead to potential adverse events. Therapeutic drug monitoring is increasingly advocated as a system to improve voriconazole dosing. However, an assay to measure voriconazole concentrations in the clinic is not routinely available. Hence, the current pilot study proposes to characterize the pharmacokinetic profile of voriconazole in obese subjects using two fixed dose regimens.
Adolescents aged 15 to 19 years have the second highest fatal drowning rate of any age group, second only to toddlers aged 12 to 36 months. This risk is amplified in black, indigenous, and people of color (BIPOC), and those of low socioeconomic status. Worcester, MA is a diverse city with over 40% of residents identifying as BIPOC and 20% living below the poverty line. The city has multiple natural bodies of water available for recreation, putting Worcester residents, particularly adolescents, at high risk of drowning. It is known that swimming lessons provided to adolescents significantly improve their swimming skills, however many programs are tailored to young children and are not appropriate for adolescents. Students from the University of Massachusetts T.H. Chan Medical School (UMass Chan), in collaboration with community partners, developed a water safety and swim education program tailored to Worcester adolescents as a means for an age-appropriate swim experience and education, community engagement, and injury prevention. Water Safe Worcester (WSW) was established as a city-wide injury prevention program that included swim lessons offered by medical students at the Central Community Branch YMCA in Worcester, MA. Instructors included UMass Chan medical students, graduate students, and staff. Adolescent YMCA members were invited to participate in lessons free of charge. Lessons were 90 min and emphasized a 3-fold approach: (1) expand knowledge of water safety and what to do in an emergency, (2) increase swimming skills, and (3) reduce fear of water. The overall attendance for the 2023 spring and summer sessions offered was 73 students, including multiple swimmers who attended more than one session. A total of 12 volunteers participated, which included 9 first-year medical students, one PhD student, one research assistant, and one surgery resident from UMass Chan. WSW demonstrated promising outcomes during its swim education classes, suggesting that WSW is a successful model to promote water safety, reduce the risk of drowning, and expand access to life-saving skills to Worcester's at-risk adolescents. This program serves as a critical step toward health equity while also providing an avenue for public health and injury prevention exposure for medical students.
BACKGROUND: The burden of Non-Communicable Diseases (NCDs) in urban informal settlements across Lower and Middle Income Countries is increasing. In recognition, there has been interest in fine-tuning policies on NCDs to meet the unique needs of people living in these settlements. To inform such policy efforts, we studied the care-seeking journeys of people living in urban informal settlements for two NCDs-diabetes and hypertension. The study was done in the Mumbai Metropolitan Region, India.
METHODS: This qualitative study was based on interviews with patients having diabetes and hypertension, supplemented by interactions with the general community, private doctors, and public sector staff. We conducted a total of 47 interviews and 6 Focus Group Discussions. We synthesized data thematically and used the qualitative software NVivo Version 10.3 to aid the process. In this paper, we report on themes that we, as a team, interpreted as striking and policy-relevant features of peoples' journeys.
RESULTS: People recounted having long and convoluted care-seeking journeys for the two NCDs we studied. There were several delays in diagnosis and treatment initiation. Most people's first point of contact for medical care were local physicians with a non-allopathic degree, who were not always able to diagnose the two NCDs. People reported seeking care from a multitude of healthcare providers (public and private), and repeatedly switched providers. Their stories often comprised multiple points of diagnosis, re-diagnosis, treatment initiation, and treatment adjustments. Advice from neighbors, friends, and family played an essential role in shaping the care-seeking process. Trade-offs between saving costs and obtaining relief from symptoms were made constantly.
CONCLUSION: Our paper attempts to bring the voices of people to the forefront of policies on NCDs. People's convoluted journeys with numerous switches between providers indicate the need for trusted "first-contact" points for NCD care. Integrating care across providers-public and private-in urban informal settlements-can go a long way in streamlining the NCD care-seeking process and making care more affordable for people. Educating the community on NCD prevention, screening, and treatment adherence; and establishing local support mechanisms (such as patient groups) may also help optimize people's care-seeking pathways.
Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
The invention provides a fused protein with extracellular fragments of a macrophage stimulating factor receptor (cFms). The fused protein is formed by connecting the cFms extracellular fragments and human immunoglobulin Fc by a connecting peptide and is named as cFmsECD-Fc. The cFms extracellular fragments are composed of at least two of five immunoglobulin (IgG) extracellular structure domains. The formed fused protein comprises YY-001, YY-002, YY-003, YY-004, YY-005, YY-006 and YY-007. The fused protein provided by the invention has functions of combining interleukin-34 (IL-34), combining the macrophage stimulating factor receptor (M-CSF) and blocking the combination of IL-34/M-CSF ligand and common receptor cFms, and is suitable for treating diseases caused by the IL-34/M-CSF under an abnormal condition. The fused protein is promising in the treatment on autoimmune diseases, inflammatory diseases, osteoporosis and tumor. And the fused protein is used for preparing medicines capable of inhibiting the inflammatory diseases, medicines capable of inhibiting the osteoporosis caused by osteoclast or medicines capable of inhibiting the growth and metastasis of the tumor.
Inflammasomes are cytoplasmic protein complexes that play a crucial role in protecting the host against pathogenic and sterile stressors by initiating inflammation. Upon activation, these complexes directly regulate the proteolytic processing and activation of proinflammatory cytokines interleukin (IL)-1β and IL-18 to induce a potent inflammatory response, and induce a programmed form of cell death called pyroptosis to expose intracellular pathogens to the surveillance of the immune system, thus perpetuating inflammation. There are various types of inflammasome complexes, with the NLRP1 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-1) inflammasome being the first one identified and currently recognized as the predominant inflammasome sensor protein in human keratinocytes. Human NLRP1 exhibits a unique domain structure, containing both an N-terminal pyrin (PYD) domain and an effector C-terminal caspase recruitment domain (CARD). It can be activated by diverse stimuli, such as viruses, ultraviolet B radiation and ribotoxic stress responses. Specific mutations in NLRP1 or related genes have been associated with rare monogenic skin disorders, such as multiple self-healing palmoplantar carcinoma; familial keratosis lichenoides chronica; autoinflammation with arthritis and dyskeratosis; and dipeptidyl peptidase 9 deficiency. Recent research breakthroughs have also highlighted the involvement of dysfunctions in the NLRP1 pathway in a handful of seemingly unrelated dermatological conditions. These range from monogenic autoinflammatory diseases to polygenic autoimmune diseases such as vitiligo, psoriasis, atopic dermatitis and skin cancer, including squamous cell carcinoma, melanoma and Kaposi sarcoma. Additionally, emerging evidence implicates NLRP1 in systemic lupus erythematosus, pemphigus vulgaris, Addison disease, Papillon-Lefèvre syndrome and leprosy. The aim of this review is to shed light on the implications of pathological dysregulation of the NLRP1 inflammasome in skin diseases and investigate the potential rationale for targeting this pathway as a future therapeutic approach.